Seltorexant

Seltorexant (also known as MIN-202) is an orexin antagonist developed by Minerva Neurosciences and Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD). It is currently in the late stages of clinical trials.

Mechanism of Action[edit | edit source]

Seltorexant works by blocking the orexin receptor, which is involved in wakefulness and arousal. By inhibiting this receptor, Seltorexant promotes sleep and has the potential to treat insomnia and other sleep disorders.

Development and Clinical Trials[edit | edit source]

Seltorexant was first developed by Minerva Neurosciences and Janssen Pharmaceutica. It has undergone several phases of clinical trials to evaluate its safety and efficacy. In Phase II trials, Seltorexant demonstrated a significant improvement in sleep onset and sleep maintenance in patients with insomnia. It is currently in Phase III trials for the treatment of insomnia and MDD.

Potential Therapeutic Uses[edit | edit source]

In addition to its potential use in treating insomnia, Seltorexant is also being investigated for its potential to treat major depressive disorder. This is due to the role of the orexin system in mood regulation. By blocking the orexin receptor, Seltorexant may help to alleviate symptoms of depression.

Side Effects[edit | edit source]

As with any medication, Seltorexant may cause side effects. These can include drowsiness, dizziness, and headache. However, these side effects are generally mild and manageable.

Future Directions[edit | edit source]

The future of Seltorexant depends on the results of ongoing clinical trials. If these trials are successful, Seltorexant could become a new treatment option for insomnia and major depressive disorder.